Patient info Open main menu

Respiporc FLUpan H1N1 - patient leaflet, side effects, dosage

Dostupné balení:

Patient leaflet - Respiporc FLUpan H1N1

B. PACKAGE LEAFLET

PACKAGE LEAFLET FOR:

RESPIPORC FLUpan H1N1 suspension for injection for pigs

  • 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder :

Ceva Santé Animale

10 av. de La Ballastière

33500 Libourne

France

Manufacturer responsible for batch release:

IDT Biologika GmbH

Am Pharmapark

06861 Dessau-Rosslau

Germany

Ceva-Phylaxia Veterinary Biologicals Co. Ltd.

Szâllâs u. 5.

1107 Budapest

Hungary

  • 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

RESPIPORC FLUpan H1N1 suspension for injection for pigs

  • 3. STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS

Each dose of 1 ml contains:

Active substance:

Inactivated Influenza A virus/human

Strain: A/Jena/VI5258/20­09(H1N1)pdm09 > 16 HU1

1 HU – haemagglutinating units.

Adjuvant:

Carbomer 971P NF 2 mg

Excipient:

Thiomersal 0.1 mg

Clear to slightly turbid, reddish to pale-pink coloured suspension.

4.


INDICATION(S)


Active immunisation of pigs from the age of 8weeks onwards against pandemic H1N1 porcine influenza virus to reduce viral lung load and virus excretion.

Onset of immunity: 7 days after primary vaccination.

Duration of immunity: 3 months after primary vaccination.

  • 5. CONTRAINDI­CATIONS

None.

  • 6. ADVERSE REACTIONS

A transient increase in rectal temperature, not exceeding 2 °C, is common after vaccination and this does not persist for more than one day.

A transient swelling up to 2 cm3 may occur at the site of injection, these reactions are common but resolve within 5 days.

The frequency of adverse reactions is defined using the following convention:

  • – very common (more than 1 in 10 animals treated displaying adverse reactions)

  • – common (more than 1 but less than 10 animals in 100 animals treated)

  • – uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

  • – rare (more than 1 but less than 10 animals in 10,000 animals treated)

  • – very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

  • 7. TARGET SPECIES

Pigs

  • 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For intramuscular use.

Vaccination: 2 injections of one dose (1 ml) from the age of 56 days, with an interval of 3 weeks between injections.

The efficacy of revaccination has not been investigated and therefore no revaccination schedule is proposed.

Maternally-derived antibodies in piglets interfere with the RESPIPORC FLUpan H1N1 mediated immunity. Generally, maternally-derived antibodies induced by vaccination last for approximately 5–8 weeks after birth.

In cases of exposure of the sows to antigens (from either field infections and/or vaccination) the antibodies transmitted to the piglets can interfere with their active vaccination at 12 weeks of age. In such cases the piglets should therefore be vaccinated after the age of 12 weeks.

  • 9. ADVICE ON CORRECT ADMINISTRATION

None.

10.


WITHDRAWAL PERIOD(S)


Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C-8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after EXP.

Shelf life after first opening the vial: 10 hours.

12.


SPECIAL WARNING(S)


Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Incompatibili­ties:

Do not mix with any other veterinary medicinal product.

  • 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE

MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

  • 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED {DD/MM/YYYY}